Kerendia
Payments companies reported to CMS as associated with Kerendia. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Kerendia, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Kerendia
These are the largest totals companies reported as associated with Kerendia. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Christian Mende | La Jolla, CA | $219,354.85 | |
| Ramon Mendez | Woodbridge, VA | Nephrology (Internal Medicine) | $196,074.12 |
| Lawrence Byrd | Livingston, NJ | Nephrology (Internal Medicine) | $171,129.56 |
| Christopher Kwoh | Houston, TX | Nephrology (Internal Medicine) | $164,591.92 |
| Narendra Singh | Johns Creek, GA | Cardiovascular Disease | $163,868.95 |
| Thomas-Duythuc To | Reno, NV | Cardiovascular Disease | $162,142.74 |
| Harvey Serota | Saint Louis, MO | Interventional Cardiology | $157,958.18 |
| Joshua Hundert | Dorchester, MA | Nephrology (Internal Medicine) | $155,408.66 |
| Biff Palmer | Dallas, TX | Nephrology (Internal Medicine) | $148,286.55 |
| Ian Neeland | Cleveland, OH | Cardiovascular Disease | $143,352.62 |
Prescribed Kerendia?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.